# Peripheral Stent Market > Peripheral Stent Market Research Report By Material (Metallic Stents, Biodegradable Stents, Polymeric Stents, Hybrid Stents), By Type (Drug-Eluting Stents, Bare Metal Stents, Covered Stents), By Application (Peripheral Artery Disease, Coronary Artery Disease, Biliary Obstruction, Ureteral Obstruction), By End Use (Hospitals, Ambulatory Surgical Centers, Specialty Clinics) By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.14% - **2024:** $ 11.43 Billion - **2025:** $ 11.79 Billion - **2035:** $ 16.07 Billion - **Key Players:** Medtronic (US), Boston Scientific (US), Abbott (US), B. Braun (DE), Terumo (JP), Cook Medical (US), Cardinal Health (US), Johnson & Johnson (US), AngioDynamics (US) **Report ID:** MRFR/HC/37276-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/peripheral-stent-market-39271 --- ## Market Summary ## **Peripheral Stent Market Overview** As per MRFR analysis, the Peripheral Stent Market Size was estimated at 11.43 (USD Billion) in 2024. The Peripheral Stent Market Industry is expected to grow from 11.79 (USD Billion) in 2025 to 15.58 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 3.14% during the forecast period (2025 - 2034).. ### **Key Peripheral Stent Market Trends Highlighted** The peripheral stent market is witnessing a significant growth driven by the rising prevalence of peripheral artery diseases, increasing geriatric population, and advancements in stent technology. Technological innovations, such as drug-eluting stents and bioresorbable stents, are enhancing procedural outcomes and driving demand. Improved healthcare infrastructure and a growing emphasis on minimally invasive procedures are also contributing to market expansion. The increasing awareness about cardiovascular health and lifestyle changes further underscores the need for effective treatments in this domain. Emerging markets present substantial opportunities for the peripheral stent market, particularly as healthcare access improves in regions like Asia-Pacific and Latin America.The rise in disposable incomes, along with government initiatives to enhance healthcare delivery, are expected to drive the adoption of peripheral stents. Companies can also explore partnerships with healthcare providers to develop tailored solutions for specific patient needs. Moreover, advancements in imaging and navigation technology are expected to improve intervention outcomes, creating pathways for new product development. Recent trends indicate a shift towards personalized medicine, with a focus on customizing stent designs and treatment plans based on patient-specific characteristics. There is also a growing preference for stents that can reduce the risk of restenosis, enhancing long-term efficacy.Additionally, the integration of digital health technologies, such as remote monitoring and telemedicine, is playing a crucial role in improving patient management. These trends suggest a dynamic market landscape where continuous innovation and patient-centric approaches will shape the future of the peripheral stent market. The focus is on improving device performance, achieving better patient outcomes, and expanding the scope of treatment options available to healthcare providers and patients alike. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Peripheral Stent Market Drivers** ### Growing Prevalence of Peripheral Vascular Diseases The increasing incidence of peripheral vascular diseases (PVDs) is a significant driver for the Peripheral Stent Market Industry. With an aging population and an increase in lifestyle-related health issues, the demand for effective vascular interventions has risen sharply. Patients suffering from conditions such as atherosclerosis, deep vein thrombosis, and critical limb ischemia require innovative treatment options, including peripheral stenting. Peripheral vascular disease (PVD) prevalence also creates a market for peripheral stents as healthcare providers aim to enhance patient outcomes and minimize the chances of complications related to this condition. The paradigm shifts further emphasize sophisticated minimally invasive modalities that accelerate recovery and shorten hospitalization periods. This trend fosters the use of peripheral stents hence impacting the growth of the market. Furthermore, improved awareness and diagnosis rates of these diseases contribute to an increased patient pool, which further escalates the demand for stenting solutions.In addition, the educational initiatives undertaken by healthcare institutions regarding the early detection and management of PVDs support an increase in interventions. Implementing advanced technologies in stent design and material science ensures that stents are more efficient, durable, and biocompatible, meeting the specific needs of PVD patients. This evolution within the Peripheral Stent Market Industry highlights a robust growth trajectory bolstered by rising disease prevalence. ### Technological Advancements in Stent Design The Peripheral Stent Market Industry is witnessing substantial growth due to significant advancements in stent technology. Innovations such as drug-eluting stents, bioabsorbable stents and improved delivery systems are enhancing the efficacy and safety of stenting procedures. These technological advancements lead to superior patient outcomes, which, in turn, boosts the adoption rate among healthcare providers and patients alike. The continuous improvement of stent materials and designs reduces complications such as restenosis and enhances the overall treatment experience for patients suffering from vascular diseases. ### Increasing Healthcare Expenditure and Investment Increasing healthcare spending in both developed and emerging markets is another vital driver for the Peripheral Stent Market Industry. Governments and private sectors are investing significantly in healthcare infrastructure, facilitating access to advanced treatment options for patients. This commitment leads to the acquisition of state-of-the-art medical devices, including peripheral stents, thus promoting their use in clinical settings. Additionally, rising demand for quality healthcare services and improvement of patient care systems inspire investments in innovative stenting solutions, further propelling market growth. ## **Peripheral Stent Market Segment Insights** ### **Peripheral Stent Market Material Insights** The Peripheral Stent Market, focusing on the Material segment, reflects an evolving landscape with significant contributions from various types of stents. In 2023, the overall market valuation highlights the pivotal role of different stent materials, which are essential for enabling effective treatments of peripheral vascular diseases. Within this framework, Metallic Stents stand out as a key player, commanding a market value of 5.0 USD Billion in 2023 and projecting growth to a value of 6.5 USD Billion by 2032. This strong position is attributed to their durability and excellent mechanical properties, making them the preferred choice in many clinical scenarios. Biodegradable Stents are also gaining momentum, valued at 3.0 USD Billion in 2023 and expected to increase to 4.0 USD Billion by 2032, reflecting a growing trend towards stents that dissolve over time, minimizing long-term complications and promoting arterial healing. Polymeric Stents, although relatively new to the market, have begun to establish their significance, starting with a valuation of 1.75 USD Billion in 2023 and moving to 2.25 USD Billion by 2032. Their biocompatibility and flexibility appeal to specific patient needs, showing a steady increase in adoption among healthcare providers. Additionally, Hybrid Stents, which combine various materials to optimize treatment outcomes, hold a value of 1.0 USD Billion in 2023, projected to rise to 1.45 USD Billion by 2032. Although this segment constitutes a smaller market share, its innovative approach to combining the advantages of different materials draws interest from clinicians focusing on tailored vascular interventions. The Peripheral Stent Market segmentation illustrates that Metallic Stents dominate the scene with a majority holding, given their established track record and reliability in procedures. Biodegradable Stents are significant for the emerging demand for less permanent solutions and safety post-implantation, capturing considerable market attention. In contrast, Polymeric Stents and Hybrid Stents represent the evolving nature of stent technology, catering to niche segments and providing opportunities for growth amidst their lesser market valuation. The interplay of these materials in the market underscores the importance of innovation and patient-specific solutions in the ongoing development and future direction of the Peripheral Stent Market industry. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Peripheral Stent Market Type Insights** The market segmentation is primarily categorized into Drug-Eluting Stents, Bare-Metal Stents and Covered Stents, each having its unique significance. Drug-Eluting Stents are recognized for their ability to minimize the risk of restenosis, thus presenting a major advantage in clinical applications, making them a preferred choice among healthcare providers. Bare-Metal Stents continue to dominate due to their cost-effectiveness and simplicity, appealing to a broad spectrum of patients and procedures. Covered Stents, while representing a smaller proportion of the market, play a crucial role in treating vascular complications and have been gaining attention for their specialized applications. The rise in cardiovascular diseases and the growing elderly population are key growth drivers for the Peripheral Stent Market. However, challenges such as stringent regulatory protocols and the high costs associated with advanced stent technologies remain prevalent. Consequently, there are significant opportunities for innovation and expanding product portfolios to enhance patient outcomes and capture a larger market share.The Peripheral Stent Market Statistics reflect these factors, showcasing its dynamic nature and potential trajectory. ### **Peripheral Stent Market Application Insights** A prominent segment encompasses the treatment of Peripheral Artery Disease and Coronary Artery Disease, where the demand remains significant due to the increasing prevalence of cardiovascular issues among an aging population. Biliary and Ureteral Obstruction are also crucial applications, addressing complications that can severely affect patient health and quality of life. Each of these areas demonstrates vital market growth, as they offer innovative solutions for improving blood flow and relieving obstructions. While the Peripheral Artery Disease segment generally commands a substantial share due to its prevalence, Coronary Artery Disease similarly reflects a growing requirement for effective stenting solutions. The rising incidences of lifestyle-related health issues globally further accentuate the need for effective intervention methods, driving the overall demand in the Peripheral Stent Market industry. Additionally, the ongoing advancements in stenting technologies present opportunities for enhancing patient outcomes, thus influencing the Peripheral Stent Market statistics favorably.Market growth within these application segments signifies a response to market needs for effective and reliable intervention methods. ### **Peripheral Stent Market End Use Insights** Hospitals play a crucial role in the market, as they are the primary setting for the majority of peripheral stent procedures, given their access to advanced technology and skilled medical professionals. Ambulatory surgical centers are increasingly gaining importance due to their ability to provide outpatient procedures, which aligns with the growing trend toward less invasive treatments and cost-effective solutions.Specialty clinics also contribute significantly, focusing on specific areas of vascular health, thereby enhancing patient outcomes through specialized care. The shift towards minimally invasive procedures and the increasing prevalence of vascular diseases are key drivers for the growth of these segments. Market growth is supported by advancements in stent technology and materials, which improve patient safety and outcomes, while challenges include stringent regulatory approvals and high costs associated with advanced stenting techniques. Overall, the Peripheral Stent Market revenue is expected to see notable gains in the coming years as these end-use segments evolve to meet patient needs more efficiently. ### **Peripheral Stent Market Regional Insights** The Peripheral Stent Market reveals a diverse regional segmentation, notably with North America holding a significant majority share, valued at 5.0 USD Billion in 2023 and projected to reach 6.5 USD Billion by 2032. This dominance is driven by advanced healthcare systems and high adoption rates of innovative medical technologies. Europe follows as another major region, with a valuation of 2.75 USD Billion in 2023, expected to grow to 3.5 USD Billion, supported by rising prevalence of vascular diseases and increasing investments in healthcare infrastructure.In the Asia-Pacific (APAC) region, the market was valued at 2.0 USD Billion in 2023 and is projected to rise to 2.75 USD Billion, reflecting growing awareness and demand for peripheral stenting procedures. South America represents a smaller segment at 0.75 USD Billion currently, anticipated to increase to 1.0 USD Billion, influenced by gradual economic growth and healthcare improvements. Meanwhile, the Middle East and Africa (MEA) segment is the least dominant, with values of 0.25 USD Billion in 2023, rising to 0.45 USD Billion, indicating emerging opportunities due to expanding healthcare services in developing nations.Overall, the regional insights into the Peripheral Stent Market segmentation underscore varied growth dynamics shaped by factors such as healthcare advancement, economic conditions and disease prevalence. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Peripheral Stent Market Key Players and Competitive Insights** The Peripheral Stent Market is characterized by intense competition as numerous players vie for market share in this rapidly evolving industry. As the demand for minimally invasive treatment options for peripheral artery disease and other vascular conditions rises, companies in this market are striving to differentiate themselves through innovation, product offerings, and strategic partnerships. Key trends influencing the competitive landscape include advancements in technology, increasing incidences of lifestyle-related diseases, and a growing elderly population that is more susceptible to vascular ailments. Furthermore, regulatory approvals and clinical efficacy play significant roles in shaping market dynamics, with companies investing heavily in research and development to enhance their product profiles and gain competitive advantages. Merit Medical Systems has established a significant presence within the Peripheral Stent Market, leveraging its strong focus on innovation and customer-centric solutions. The company is recognized for its comprehensive portfolio of peripheral vascular interventions, which includes advanced stenting systems designed to meet diverse clinical needs. Merit Medical Systems emphasizes the quality and reliability of its products, backed by a dedication to improving patient outcomes. The company's established relationships with healthcare professionals and strong distribution channels enhance its market penetration and allow for better visibility within the healthcare landscape. By continuously investing in new technologies and expanding its product offerings, Merit Medical Systems is well-positioned to capitalize on emerging opportunities in the peripheral stent sector.Abbott Laboratories has marked its presence in the Peripheral Stent Market by focusing on technological advancements and innovative treatment solutions. The company is dedicated to developing cutting-edge stent systems that provide enhanced deliverability, greater flexibility, and improved patient outcomes. Abbott Laboratories’ strong commitment to research and development has led to the introduction of several novel products that address the evolving needs of clinicians and patients alike. Additionally, Abbott Laboratories benefits from its well-established reputation in the medical device industry, which aids in gaining the trust of healthcare providers. With a footprint and a diversified product line, Abbott Laboratories continues to play a pivotal role in shaping the competitive landscape of the peripheral stent market while aiming to enhance the standard of care for patients with vascular diseases. ### **Key Companies in the Peripheral Stent Market Include** - Merit Medical Systems - **[Abbott Laboratories](https://www.cardiovascular.abbott/us/en/hcp/products/peripheral-intervention/peripheral-stents.html)** - Zephyr Surgery - Biosensors International - R. Bard - Cardinal Health - L. Gore and Associates - SentreHEART - Cook Medical - Braun Melsungen - Terumo - Boston Scientific - Philips - Medtronic - Acandis ## Peripheral Stent Market Industry Developments - **Q2 2024: Boston Scientific Announces FDA Approval of Ranger™ Drug-Coated Balloon for Peripheral Artery Disease** Boston Scientific received FDA approval for its Ranger™ Drug-Coated Balloon, designed to treat patients with peripheral artery disease in the superficial femoral and popliteal arteries. The approval expands the company's portfolio of peripheral vascular intervention devices. - **Q2 2024: Medtronic Receives CE Mark for Onyx Frontier™ Drug-Eluting Stent System** Medtronic announced it has received CE Mark approval for its Onyx Frontier™ Drug-Eluting Stent System, which is indicated for use in peripheral vascular interventions. The approval allows Medtronic to market the device in the European Union. - **Q2 2024: BD Launches New Peripheral Vascular Stent System in Europe** BD announced the commercial launch of its new peripheral vascular stent system in select European markets. The device is designed to improve vessel patency in patients with peripheral artery disease. - **Q3 2024: Abbott Receives FDA Approval for Esprit BTK Everolimus Eluting Bioresorbable Scaffold System** Abbott received FDA approval for its Esprit BTK Everolimus Eluting Bioresorbable Scaffold System, intended for the treatment of below-the-knee peripheral artery disease. This marks a significant regulatory milestone for bioresorbable stent technology in the U.S. - **Q3 2024: Terumo Launches Ultimaster Tansei™ Drug-Eluting Stent in Japan for Peripheral Artery Disease** Terumo announced the launch of its Ultimaster Tansei™ Drug-Eluting Stent in Japan, expanding its peripheral vascular product offerings in the Japanese market. - **Q4 2024: Cook Medical Announces U.S. Launch of Zilver® PTX® Drug-Eluting Peripheral Stent** Cook Medical launched its Zilver® PTX® Drug-Eluting Peripheral Stent in the United States, following recent FDA approval. The stent is indicated for use in the treatment of peripheral artery disease in the femoropopliteal artery. - **Q4 2024: Cordis Announces Strategic Partnership with MedAlliance for Peripheral Drug-Eluting Stent Distribution** Cordis entered into a strategic partnership with MedAlliance to distribute MedAlliance's peripheral drug-eluting stent products in select global markets, aiming to expand access to advanced stent technologies. - **Q1 2025: Biotronik Receives CE Mark for Pulsar-18 T3 Peripheral Self-Expanding Stent System** Biotronik announced CE Mark approval for its Pulsar-18 T3 Peripheral Self-Expanding Stent System, enabling commercialization in the European Union for the treatment of peripheral artery disease. - **Q1 2025: Boston Scientific Launches Eluvia™ Drug-Eluting Vascular Stent in Asia-Pacific** Boston Scientific launched its Eluvia™ Drug-Eluting Vascular Stent in the Asia-Pacific region, expanding its global reach in the peripheral stent market. - **Q2 2025: Medtronic Announces FDA Approval of IN.PACT™ AV Drug-Coated Balloon for Peripheral Vascular Disease** Medtronic received FDA approval for its IN.PACT™ AV Drug-Coated Balloon, designed to treat peripheral vascular disease in arteriovenous fistulae for hemodialysis patients. - **Q2 2025: Abbott Launches New Generation Xience Skypoint™ Stent for Peripheral Artery Disease in Europe** Abbott announced the European launch of its new generation Xience Skypoint™ Stent, designed for the treatment of peripheral artery disease, following CE Mark approval. - **Q2 2025: Terumo Opens New Manufacturing Facility for Peripheral Vascular Devices in Vietnam** Terumo Corporation opened a new manufacturing facility in Vietnam dedicated to the production of peripheral vascular devices, aiming to meet growing global demand. ## **Peripheral Stent Market Segmentation Insights** ### **Peripheral Stent Market Material Outlook** - Metallic Stents - Biodegradable Stents - Polymeric Stents - Hybrid Stents ### **Peripheral Stent Market Type Outlook** - Drug-Eluting Stents - Bare-Metal Stents - Covered Stents **Peripheral Stent Market Application Outlook** - [Peripheral Artery Disease](../../../reports/peripheral-artery-disease-market-1540) - Coronary Artery Disease - Biliary Obstruction - Ureteral Obstruction ### **Peripheral Stent Market End Use Outlook** - Hospitals - Ambulatory Surgical Centers - Specialty Clinics ### **Peripheral Stent Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa -   -   -   -   -   - Beta Beta feature -   -   -   -   -   - Beta Beta feature ## Market Drivers ### Increasing Healthcare Expenditure Rising healthcare expenditure across various regions is a crucial driver for the Peripheral Stent Market. As governments and private sectors allocate more resources to healthcare, the availability of advanced medical technologies, including peripheral stents, is improving. This increase in funding facilitates the adoption of innovative stenting solutions, which are essential for treating conditions like PAD. Recent data indicates that healthcare spending is projected to grow at an annual rate of approximately 5% through 2025, thereby enhancing access to advanced medical treatments. This trend is likely to bolster the Peripheral Stent Market, as healthcare providers invest in state-of-the-art technologies to meet the growing demand for effective treatment options. ### Regulatory Support and Approval Processes Regulatory support and streamlined approval processes are vital factors influencing the Peripheral Stent Market. Regulatory bodies are increasingly recognizing the importance of innovative stenting technologies and are working to expedite the approval of new devices. This supportive environment encourages manufacturers to invest in research and development, leading to the introduction of advanced stent designs that meet evolving patient needs. Recent initiatives aimed at reducing the time required for clinical trials and approvals could potentially enhance market entry for new products. As a result, the Peripheral Stent Market is likely to benefit from a more dynamic and competitive landscape, fostering innovation and improving patient care. ### Technological Innovations in Stent Design Technological advancements in stent design are significantly influencing the Peripheral Stent Market. Innovations such as drug-eluting stents, bioresorbable stents, and advanced materials are enhancing the efficacy and safety of stenting procedures. These innovations not only improve patient outcomes but also reduce the risk of restenosis, a common complication associated with traditional stents. The market has witnessed a surge in the adoption of these advanced stents, with estimates indicating that the drug-eluting stent segment alone could account for over 60% of the market share by 2025. As healthcare providers increasingly favor these cutting-edge solutions, the Peripheral Stent Market is likely to experience robust growth driven by technological progress. ### Rising Incidence of Peripheral Artery Disease The increasing prevalence of peripheral artery disease (PAD) is a primary driver for the Peripheral Stent Market. As populations age, the incidence of PAD, which affects millions worldwide, continues to rise. This condition often leads to severe complications, necessitating effective treatment options. The Peripheral Stent Market is poised to benefit from this trend, as stenting procedures are commonly employed to restore blood flow in affected arteries. Recent estimates suggest that the number of PAD cases could reach over 200 million by 2025, thereby amplifying the demand for peripheral stents. This growing patient population underscores the need for innovative stent technologies that can enhance patient outcomes and reduce the risk of complications, further propelling market growth. ### Growing Preference for Minimally Invasive Procedures The shift towards minimally invasive procedures is a significant factor driving the Peripheral Stent Market. Patients and healthcare providers alike are increasingly favoring these techniques due to their associated benefits, such as reduced recovery times, lower risk of complications, and minimal scarring. As a result, the demand for peripheral stenting procedures is on the rise, with projections indicating that the market could expand at a compound annual growth rate of over 8% through 2025. This trend is further supported by advancements in imaging technologies and catheter-based techniques, which enhance the precision and effectiveness of stenting procedures. Consequently, the Peripheral Stent Market is well-positioned to capitalize on this growing preference for less invasive treatment options. ## Future Outlook The Peripheral Stent Market is projected to grow at a 3.14% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of vascular diseases, and rising healthcare expenditures. **New opportunities:** - Development of biodegradable stents for enhanced patient outcomes. Expansion into emerging markets with tailored product offerings. Integration of AI-driven analytics for personalized treatment plans. By 2035, the Peripheral Stent Market is expected to achieve robust growth, reflecting evolving healthcare needs. ## Segment Insights ### By Material: Metallic Stents (Largest) vs. Biodegradable Stents (Fastest-Growing) The Peripheral Stent Market reveals a distinct distribution among different material segments, with Metallic Stents leading the way as the largest segment. They dominate market share due to their established performance, durability, and widespread clinical use, thereby gaining a significant share of the market. Meanwhile, Biodegradable Stents are making waves by rapidly gaining traction, capturing the attention of health practitioners and patients alike, thanks to their innovative design that promotes natural healing processes. Stent Type: Metallic (Dominant) vs. Biodegradable (Emerging) Metallic Stents are characterized by their robust construction, ensuring longevity and reliability within the vascular system. They come in various designs, facilitating versatility in treating different conditions. Their existing market penetration is supported by extensive clinical data, showcasing their effectiveness in preventing restenosis. Conversely, Biodegradable Stents represent an emerging technology that offers unique advantages by gradually dissolving after serving their purpose. This feature minimizes long-term complications and aligns with contemporary health trends favoring less invasive solutions. Their increasing adoption is being fueled by ongoing advances in material science and a growing emphasis on personalized medicine. ### By Type: Drug-Eluting Stents (Largest) vs. Bare-Metal Stents (Fastest-Growing) The Peripheral Stent Market currently exhibits a diverse distribution of share among its key segments: Drug-Eluting Stents (DES), Bare-Metal Stents (BMS), and Covered Stents. Among these, Drug-Eluting Stents hold the largest portion, reflecting their widespread adoption and preference due to their drug-coated mechanisms, which help prevent restenosis. Conversely, Bare-Metal Stents have emerged as the fastest-growing segment, primarily driven by cost-effectiveness and widespread applicability in various clinical scenarios. This dynamic has led to a competitive landscape where DES retains a significant lead, but BMS is gaining traction rapidly. As we look to future trends, the growth of Bare-Metal Stents is fueled by an increasing number of procedures requiring fast and straightforward implantation without the complexities associated with drug-eluting solutions. The rising prevalence of peripheral artery disease (PAD) and the need for interventions in a growing elderly population are pivotal drivers propelling this segment forward. Furthermore, technical advancements and a push towards reducing healthcare costs are prompting clinicians to consider BMS as a viable and efficient option in many instances, thereby boosting their market position. Stent Type: Drug-Eluting Stents (Dominant) vs. Bare-Metal Stents (Emerging) Drug-Eluting Stents (DES) have established themselves as the dominant player in the Peripheral Stent Market due to their advanced technology that reduces the risk of restenosis through localized drug delivery. These stents are increasingly favored in complex arterial disease cases, providing patients with improved long-term outcomes. Meanwhile, Bare-Metal Stents (BMS) are viewed as an emerging segment gaining traction rapidly due to their simpler construction, lower costs, and minimal surgical demands. With healthcare systems focusing on cost-effectiveness and efficient patient management, BMS are appealing for routine applications. Both stent types serve distinct roles, with DES positioned for high complexity procedures and BMS tailored for broader usage, reflecting a balanced approach in achieving optimal patient care. ### By Application: Peripheral Artery Disease (Largest) vs. Biliary Obstruction (Fastest-Growing) In the Peripheral Stent Market, the application segment illustrates significant diversity, with Peripheral Artery Disease (PAD) taking the lead in market share due to its widespread prevalence and necessity for intervention. Following PAD, Coronary Artery Disease has established a notable presence, while Biliary and Ureteral Obstructions are gaining traction but currently hold smaller shares. The variations in application reflect the unique challenges and needs faced by patients in securing adequate vascular treatment. Peripheral Artery Disease (Dominant) vs. Biliary Obstruction (Emerging) Peripheral Artery Disease (PAD) emerges as the dominant player in the Peripheral Stent Market, underpinned by its high patient incidence and the robust demand for treatment options that alleviate blood flow issues in the legs. The effective treatment of PAD with stents has bolstered its market posture. In contrast, Biliary Obstruction represents an emerging segment, driven by increasing awareness and technological advancements in stenting techniques. Although it is currently smaller in comparison, its growth trajectory is steep, propelled by rising incidences of biliary diseases and a corresponding surge in patient referrals to interventional procedures. ### By End Use: Hospitals (Largest) vs. Specialty Clinics (Fastest-Growing) In the Peripheral Stent Market, hospitals command the largest share of the end-use segment. This dominance is due to their extensive resources, advanced technology, and comprehensive patient care facilities that can handle complex procedures. Hospitals typically contribute significantly to the volume of stent procedures performed, as they are often equipped with specialized teams and infrastructure required for high-complexity cardiovascular interventions. On the other hand, ambulatory surgical centers, while smaller in market share, are quickly growing as they offer specialized services in a more efficient and cost-effective manner. Growth trends in this segment are being propelled by increasing patient awareness, technological advancements, and a shift towards outpatient care models. As more peripheral vascular procedures transition from inpatient to outpatient settings, ambulatory surgical centers are experiencing rapid growth. Specialty clinics are also emerging as key players, driven by their focused services and personalized care, appealing to patients seeking less invasive options and shorter recovery times. Hospitals (Dominant) vs. Specialty Clinics (Emerging) Hospitals' dominant position in the Peripheral Stent Market is attributed to their all-encompassing capabilities that can cater to a wide range of cardiovascular interventions. They provide a full spectrum of services, from diagnosis to surgical procedures, equipped with cutting-edge technology and a team of specialized healthcare professionals. In contrast, specialty clinics are gaining momentum as emerging players, catering specifically to vascular procedures. These clinics often focus on delivering cost-effective care and shorter wait times, appealing to an increasingly informed patient base that favors less invasive treatments. The growing trend towards personalized healthcare is propelling specialty clinics to refine their offerings and enhance patient experience, positioning them as attractive alternatives within the broader healthcare landscape. ## Regional Market Share Analysis ### North America : Market Leader in Innovation North America is the largest market for peripheral stents, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of peripheral artery diseases, and a strong focus on innovation. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring the availability of cutting-edge technologies and treatments. The United States is the primary contributor to this market, with key players such as Medtronic, Boston Scientific, and Abbott leading the competitive landscape. The presence of these major companies fosters a robust environment for research and development, enhancing product offerings. Additionally, the growing aging population and rising healthcare expenditure are expected to sustain demand for peripheral stents in the coming years. ### Europe : Emerging Market Dynamics Europe is witnessing significant growth in the peripheral stent market, holding approximately 30% of the global share. The region benefits from a well-established healthcare system, increasing awareness of peripheral artery diseases, and supportive regulatory frameworks. Countries like Germany and France are at the forefront, driving demand through advanced medical technologies and innovative treatment options. Germany leads the market, supported by a strong presence of key players such as B. Braun and Terumo. The competitive landscape is characterized by collaborations and partnerships among companies to enhance product offerings. Additionally, the European Union's Medical Device Regulation ensures high standards for safety and efficacy, further boosting market confidence and adoption rates. ### Asia-Pacific : Rapidly Growing Market Asia-Pacific is emerging as a significant player in the peripheral stent market, accounting for around 20% of the global share. The region's growth is fueled by increasing healthcare investments, rising prevalence of cardiovascular diseases, and a growing aging population. Countries like Japan and China are leading this growth, supported by government initiatives aimed at improving healthcare access and quality. Japan stands out with its advanced healthcare infrastructure and a strong focus on research and development. Key players such as Terumo and Cook Medical are actively expanding their presence in the region. The competitive landscape is evolving, with local manufacturers also entering the market, enhancing competition and driving innovation in product offerings. ### Middle East and Africa : Untapped Market Potential The Middle East and Africa region is gradually emerging in the peripheral stent market, holding about 5% of the global share. The growth is driven by increasing healthcare investments, rising awareness of cardiovascular diseases, and improving healthcare infrastructure. Countries like South Africa and the UAE are leading the way, with government initiatives aimed at enhancing healthcare services and access to advanced medical technologies. South Africa is a key player in this market, with a growing number of healthcare facilities adopting advanced stenting technologies. The competitive landscape is characterized by a mix of local and international players, including Johnson & Johnson and AngioDynamics. As healthcare systems continue to evolve, the demand for peripheral stents is expected to rise, presenting significant opportunities for market expansion. ## Competitive Benchmarking The Peripheral Stent Market is characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of peripheral artery diseases, and a growing aging population. Major players such as [Medtronic](https://www.medtronic.com/en-us/healthcare-professionals/products/cardiovascular/peripheral-biliary-stents.html)(US), Boston Scientific (US), and Abbott (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Medtronic (US) focuses on innovation through the development of next-generation stent technologies, while Boston Scientific (US) emphasizes strategic partnerships to expand its product offerings. Abbott (US) is leveraging its strong research and development capabilities to introduce cutting-edge solutions, thereby shaping a competitive environment that prioritizes technological superiority and patient outcomes.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to thrive, while larger companies consolidate their positions through mergers and acquisitions, thereby intensifying competition. In August Medtronic (US) announced the launch of its latest peripheral stent, which incorporates advanced bioresorbable technology aimed at improving patient recovery times. This strategic move not only reinforces Medtronic's commitment to innovation but also positions the company to capture a larger share of the market by addressing the growing demand for minimally invasive solutions. The introduction of this product is likely to enhance Medtronic's competitive edge, particularly in regions with high rates of peripheral artery disease. In September Boston Scientific (US) entered into a collaboration with a leading digital health company to integrate AI-driven analytics into its stent monitoring systems. This partnership is indicative of a broader trend towards digital transformation within the industry, as it aims to provide healthcare professionals with real-time data to optimize patient care. By embracing digital solutions, Boston Scientific (US) is not only enhancing its product offerings but also positioning itself as a leader in the integration of technology and healthcare. In July Abbott (US) completed the acquisition of a smaller firm specializing in innovative stent delivery systems. This acquisition is strategically significant as it expands Abbott's portfolio and enhances its capabilities in delivering advanced stent technologies. The move reflects a growing trend of consolidation within the market, as companies seek to bolster their competitive positions through strategic acquisitions that enhance their technological capabilities and market reach. As of October the Peripheral Stent Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to leverage complementary strengths and enhance their product offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet the demands of a rapidly changing healthcare environment. ## Recent News & Developments - **Q2 2024: Boston Scientific Announces FDA Approval of Ranger™ Drug-Coated Balloon for Peripheral Artery Disease** Boston Scientific received FDA approval for its Ranger™ Drug-Coated Balloon, designed to treat patients with peripheral artery disease in the superficial femoral and popliteal arteries. The approval expands the company's portfolio of peripheral vascular intervention devices. - **Q2 2024: Medtronic Receives CE Mark for Onyx Frontier™ Drug-Eluting Stent System** Medtronic announced it has received CE Mark approval for its Onyx Frontier™ Drug-Eluting Stent System, which is indicated for use in peripheral vascular interventions. The approval allows Medtronic to market the device in the European Union. - **Q2 2024: BD Launches New Peripheral Vascular Stent System in Europe** BD announced the commercial launch of its new peripheral vascular stent system in select European markets. The device is designed to improve vessel patency in patients with peripheral artery disease. - **Q3 2024: Abbott Receives FDA Approval for Esprit BTK Everolimus Eluting Bioresorbable Scaffold System** Abbott received FDA approval for its Esprit BTK Everolimus Eluting Bioresorbable Scaffold System, intended for the treatment of below-the-knee peripheral artery disease. This marks a significant regulatory milestone for bioresorbable stent technology in the U.S. - **Q3 2024: Terumo Launches Ultimaster Tansei™ Drug-Eluting Stent in Japan for Peripheral Artery Disease** Terumo announced the launch of its Ultimaster Tansei™ Drug-Eluting Stent in Japan, expanding its peripheral vascular product offerings in the Japanese market. - **Q4 2024: Cook Medical Announces U.S. Launch of Zilver® PTX® Drug-Eluting Peripheral Stent Market** Cook Medical launched its Zilver® PTX® Drug-Eluting Peripheral Stent Market in the United States, following recent FDA approval. The stent is indicated for use in the treatment of peripheral artery disease in the femoropopliteal artery. - **Q4 2024: Cordis Announces Strategic Partnership with MedAlliance for Peripheral Drug-Eluting Stent Distribution** Cordis entered into a strategic partnership with MedAlliance to distribute MedAlliance's peripheral drug-eluting stent products in select global markets, aiming to expand access to advanced stent technologies. - **Q1 2025: Biotronik Receives CE Mark for Pulsar-18 T3 Peripheral Self-Expanding Stent System** Biotronik announced CE Mark approval for its Pulsar-18 T3 Peripheral Self-Expanding Stent System, enabling commercialization in the European Union for the treatment of peripheral artery disease. - **Q1 2025: Boston Scientific Launches Eluvia™ Drug-Eluting Vascular Stent in Asia-Pacific** Boston Scientific launched its Eluvia™ Drug-Eluting Vascular Stent in the Asia-Pacific region, expanding its global reach in the peripheral stent market. - **Q2 2025: Medtronic Announces FDA Approval of IN.PACT™ AV Drug-Coated Balloon for Peripheral Vascular Disease** Medtronic received FDA approval for its IN.PACT™ AV Drug-Coated Balloon, designed to treat peripheral vascular disease in arteriovenous fistulae for hemodialysis patients. - **Q2 2025: Abbott Launches New Generation Xience Skypoint™ Stent for Peripheral Artery Disease in Europe** Abbott announced the European launch of its new generation Xience Skypoint™ Stent, designed for the treatment of peripheral artery disease, following CE Mark approval. - **Q2 2025: Terumo Opens New Manufacturing Facility for Peripheral Vascular Devices in Vietnam** Terumo Corporation opened a new manufacturing facility in Vietnam dedicated to the production of peripheral vascular devices, aiming to meet growing global demand. ## Report Scope | MARKET SIZE 2024 | 11.43(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 11.79(USD Billion) | | MARKET SIZE 2035 | 16.07(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.14% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Medtronic (US), Boston Scientific (US), Abbott (US), B. Braun (DE), Terumo (JP), Cook Medical (US), Cardinal Health (US), Johnson & Johnson (US), AngioDynamics (US) | | Segments Covered | Material, Type, Application, End Use, Regional | | Key Market Opportunities | Advancements in biodegradable materials enhance safety and efficacy in the Peripheral Stent Market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the Peripheral Stent Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of the Peripheral Stent Market by 2035?** A: The Peripheral Stent Market is projected to reach a valuation of 16.07 USD Billion by 2035. **Q: What was the market valuation of the Peripheral Stent Market in 2024?** A: In 2024, the Peripheral Stent Market was valued at 11.43 USD Billion. **Q: What is the expected CAGR for the Peripheral Stent Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Peripheral Stent Market during the forecast period 2025 - 2035 is 3.14%. **Q: Which companies are considered key players in the Peripheral Stent Market?** A: Key players in the Peripheral Stent Market include Medtronic, Boston Scientific, Abbott, B. Braun, Terumo, Cook Medical, Cardinal Health, Johnson & Johnson, and AngioDynamics. **Q: What are the projected revenues for Metallic Stents by 2035?** A: The projected revenues for Metallic Stents are expected to rise from 5.0 USD Billion in 2024 to 7.0 USD Billion by 2035. **Q: How do Drug-Eluting Stents compare to Bare-Metal Stents in terms of market valuation?** A: Drug-Eluting Stents are projected to grow from 4.57 USD Billion in 2024 to 6.5 USD Billion by 2035, whereas Bare-Metal Stents are expected to increase from 3.43 USD Billion to 4.5 USD Billion. **Q: What is the anticipated market size for Peripheral Artery Disease applications by 2035?** A: The market size for Peripheral Artery Disease applications is anticipated to grow from 3.43 USD Billion in 2024 to 4.57 USD Billion by 2035. **Q: What segment is expected to have the highest revenue growth in the Peripheral Stent Market?** A: The segment of Drug-Eluting Stents is expected to have the highest revenue growth, projected to reach 6.5 USD Billion by 2035. **Q: What is the expected market size for Ambulatory Surgical Centers by 2035?** A: The expected market size for Ambulatory Surgical Centers is projected to increase from 3.25 USD Billion in 2024 to 4.5 USD Billion by 2035. **Q: How does the market for Hybrid Stents project to grow by 2035?** A: The market for Hybrid Stents is projected to grow from 1.93 USD Billion in 2024 to 2.57 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/peripheral-stent-market-39271*